亚洲国产精品一区二区久久hs,精品国产一级在线观看,免 费 成人黄 色 大片,不卡中文一二三区,国产剧情麻豆mv在线观看,久久久久久久久久久精品,久久九九综合,久久久久久91香蕉国产

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購物車 1 種商品 - 共0元
當(dāng)前位置: 首頁 > 行業(yè)資訊 > Personalized medicine: Testing therapies on mini-tumors of h

Personalized medicine: Testing therapies on mini-tumors of h

 Date:

June 17, 2019
Source:
Hubrecht Institute
Summary:

Head and neck cancer is an aggressive type of cancer that often recurs, despite patients undergoing harsh treatments. Researchers have succeeded in growing mini-tumors (or organoids) of head and neck cancers, that can be kept alive in the petri-dish for a long time. These mini-tumor were shown to predict patient response to therapy. Thus, this technique holds promise to identify the right therapy for the right patient.

Head and neck cancer is an aggressive type of cancer that often grows back, despite patients undergoing harsh treatments. Researchers of the Hubrecht Institute (KNAW) and UMC Utrecht succeeded in growing mini-tumors (or organoids) of head and neck cancers, that can be kept alive in the petri-dish for a long time. Else Driehuis, researcher at the Hubrecht Institute: "These mini-tumors can be used to better understand this complex disease. Moreover, organoids allow us to test both novel and existing therapies in the lab, without burdening the patient."

Head and neck cancer is amongst the ten most prevalent cancers in the world. In the Netherlands, more than 3000 people are diagnosed with this disease every year. Despite heavy treatments that include surgery, radiotherapy and chemotherapy, this aggressive type of cancer grows back within two years in 40 to 60% of the patients. This results in problems with speaking and swallowing and can have large consequences for the physical appearance of the patient. "The treatment of head and neck cancer is harsh," according to medical oncologist Lot Devriese (UMC Utrecht). Often, a combination of therapies is required to treat the disease and this can result in serious side effects. Therefore, there is an urgent need to make treatments more effective and decrease side effects."

Surgery

Researchers working in the group of Hans Clevers (Hubrecht Institute) and doctors and researchers from the UMC Utrecht have now shown that organoids can be grown from so-called head and neck squamous cell carcinomas (HNSCC). These mini-organs are derived from patient-material, for example obtained from the tumor mass removed during surgery. Tumor-organoids of thirty patients diagnosed with head and neck cancer have been kept in culture for over a year. "This is the first time that researchers have been successful in growing organoids derived from head and neck cancer on this scale" says pathologist Stefan Willems (UMC Utrecht). "This technique allows us to multiply the tumor cells of a patient in the lab and will contribute to our understanding of head and neck cancer."

Radiotherapy

After growing the mini-tumors, they were exposed to chemotherapies that are currently given to patients with head and neck cancer. Since radiotherapy is also a common component of the treatment of these patients, the organoids were also exposed to radiotherapy. For seven patients their response to radiotherapy was known. Upon exposure to this therapy, the organoids derived from these patients behaved in the same way as the tumors in these patients did. "We have now started a study in which we will include more patients, to see if organoids can indeed predict the patients response to therapy," says Else Driehuis (Hubrecht Institute)." At the moment, many patients are exposed to harsh chemotherapeutics, whereas some of them in hindsight did not benefit from this therapy. In the lab, we can test many different drugs at the same time to see how the tumor-organoids of the patient respond to them. Potentially, such tests can help us to choose the right therapy for each individual patient."

Predicting patient response

The researchers also exposed the mini-tumors to a range of novel drugs, so-called 'targeted therapies'. As the name implies, these drugs have a very targeted effect and therefore cause less severe side effects than conventional chemotherapies. The downside: they only work for a subset of patients that carry specific alterations in the DNA of their tumor. "For some of these drugs, it has proven difficult to predict which patients will benefit from the treatment. Unfortunately, this has limited the success of these promising therapies so far" says Driehuis. "In our study, we observed that each of the drugs we tested was effective in the organoids of at least one patient. More research will tell us if the tumor-organoids can also predict the patient response for these therapies."

Story Source:

Materials provided by Hubrecht InstituteNote: Content may be edited for style and length.


Journal Reference:

  1. Else Driehuis, Sigrid Kolders, Sacha Spelier, Kadi Lõhmussaar, Stefan M. Willems, Lot A. Devriese, Remco de Bree, Emma J. de Ruiter, Jeroen Korving, Harry Begthel, Johan H. van Es, Veerle Geurts, Gui-Wei He, Richard H. van Jaarsveld, Rurika Oka, Mauro J. Muraro, Judith Vivié, Maurice M.J.M. Zandvliet, Antoni P.A. Hendrickx, Nino Iakobachvili, Priya Sridevi, Onno Kranenburg, Ruben van Boxtel, Geert J.P.L. Kops, David A. Tuveson, Peter J. Peters, Alexander van Oudenaarden, Hans Clevers. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer TherapyCancer Discovery, 2019; DOI: 10.1158/2159-8290.CD-18-1522
芜湖县| 祁东县| 晋中市| 枣阳市| 始兴县| 红安县| 天津市| 洮南市| 浠水县| 乌鲁木齐县| 新乡市| 宁乡县| 靖西县| 留坝县| 天等县| 邳州市| 金沙县| 茂名市| 惠水县| 米脂县| 任丘市| 沅陵县| 庆元县| 横峰县| 尤溪县| 青海省| 黄浦区| 安陆市| 广平县| 奎屯市| 宝应县| 娱乐| 高安市| 齐河县| 西乡县| 同心县| 天等县| 体育| 伊吾县| 彭山县| 克拉玛依市|